PVR and neoplasm: Multiple checkpoint ligands are upregulated on tumor cells by IFNy, including Qa-1b, which binds NKG2A/CD94 on NK cells and activated CD8+ effector T cells22 and CD155, which interacts with the T cell immunoreceptor with Ig and ITIM domains (TIGIT) 52.